News

Self-driving labs enable faster and smarter polymer synthesis
Research into chemical discovery, testing optimization and analysis can be a labor-intensive and time-consuming process. With ...
The Manila Times3h
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today ...
OpenAI and FDA to Use AI in Drug Evaluation
The US federal agency responsible for regulating medicines wants to speed up the evaluation process using the cderGPT ...
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.
PharmExec3d
Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain
Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...
The Manila Times4d
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
Ophthalmology Times4d
Phase 2 data on IBI302 announced by Innovent Biologics
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
modernretina5d
Innovent Biologics announced latest data on IBI302
The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose ... The study lasted 52 weeks. “Current drug development focuses on multi-target strategies and ...